RPE65 and Leber congenital amaurosis: Luxturna, a medication developed by Spark Therapeutics Inc. (Philadelphia, PA, USA), which got FDA approval for the treatment of RPE65-associated Leber congenital amaurosis (LCA), best shows the efficacy of this approach [3,33].